ArticleNeurogenetics2025
A novel VPS13A mutation in an Iranian family with Chorea-Acanthocytosis.
Article in Neurogenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chorea-Acanthocytosis (ChAc) is a rare genetic disorder characterized by progressive neurodegeneration and acanthocytosis in the bloodstream. Biallelic mutations in the Vacuolar Protein Sorting 13 homolog A (VPS13A) gene have been identified as the cause of ChAc. This study aims to report a novel mutation in VPS13A associated with ChAc in two Iranian brothers. Two brothers from an Iranian family, aged 31 and 32, presented with clinical features suggestive of ChAc, including progressive chorea, cognitive decline, and seizures. Whole exome sequencing revealed a novel homozygous frameshift mutation in exon 47 of VPS13A (NM 0018037. 2: c. 6348delA, p. K2117Nfs*16) in both brothers. However, both parents resulted heterozygous carriers. This report describes a previously unreported homozygous frameshift mutation in VPS13A associated with ChAc. This finding broadens the known mutational landscape of VPS13A in the Iranian population and underscores the value of genetic screening in patients with suspected neuroacanthocytosis syndromes.
Indexed as
Identifiers
41123725What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.